Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Radioligand (11C)AZD2995
Radioligand AZD2995 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | OTHER | Alzheimer's Disease (AD) patients |
| 2 | OTHER | Healthy volunteers |
| Name | Type | Description |
|---|---|---|
| Radioligand (11C)AZD2995 | DRUG | Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers. |
| Radioligand (11C)AZD2184 | DRUG | Single dose of i.v solution. Once for AD patients respective healthy volunteers. |
Inclusion Criteria: * Alzheimer´s Disease patients - 50-85 years- mild to moderate AD, clinical progression of AD over 12 months. * Healthy male volunteers: - Age 20-50 years, Body Mass Index: 18-30 kg/m2. * Clinically normal physical findings including normal blood pressure and pulse rate. Exclus...
Top 20 of 30 competitors
Radioligand AZD2995 is an investigational small molecule positron emission tomography (PET) ligand developed by AstraZeneca PLC. It is designed for brain imaging in Alzheimer's disease research and is also known as Radioligand (11C)AZD2995. It is a Phase 1 imaging agent, not a therapeutic treatment.
Radioligand AZD2995 is used as a PET imaging agent in Alzheimer's disease research. It is designed to bind beta-amyloid in the brain, allowing visualization of amyloid plaques via PET scans. It is an investigational imaging ligand, not a therapy for treating Alzheimer's disease.
Radioligand AZD2995 is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca is the sponsor of the clinical trial evaluating this PET ligand.
Radioligand AZD2995 is in Phase 1 clinical development. It has completed one Phase 1 trial and is investigational; it is not approved by the FDA. The completed trial was a PET imaging study in Alzheimer's disease.
Radioligand AZD2995 has been evaluated in one completed Phase 1 trial, NCT00692705, titled "Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid." The trial enrolled 13 participants in Sweden and included healthy volunteers.
Yes, Radioligand AZD2995 is also known as Radioligand (11C)AZD2995. The (11C) notation indicates the carbon-11 radioisotope used in the molecule for PET imaging. Both names refer to the same investigational imaging agent developed by AstraZeneca.